Clinical trial
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
NCT00227591 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00227591 |
|---|---|
| Title | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis |
| Official title | A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis |
| Intervention type | Drug, Other |
| Interventions | lenalidomide, prednisone, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Sep 28, 2005 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: